I have devoted my career studying viral infections in cancer patients, specifically those undergoing hematopoietic cell transplantation (HCT) for hematologic malignancies. I have published extensively on mechanisms to treat and prevent viral infections in this population. During my tenure at MD Anderson, I have established the clinical virology research program and assembled a research team that conducts phase II and phase III clinical trials for new antiviral drugs, desperately needed for our immunocompromised patients. I have lead and completed a multi-institutional and international phase II trial for a new investigational antiviral drug, Letermovir, for prevention of CMV reactivation in allogeneic HCT recipients (New England Journal of Medicine, 2014). With strong collaboration with the Stem Cell Transplantation and Cellular Therapy Department (Drs. Champlin, Shpall, Rezvani and Hosing), I have successfully completed more than 11 clinical trials and several studies focusing on diagnosis and management of viral infections; data from which have been presented nationally and internationally with subsequent publications in high-impact journals. I have extensive research background in virology, with specific training and expertise in key research areas for this application. I have a proven track record of collaboration with Dr. Boeckh, most relevantly on recently published large multicenter CMV prevention trial, and we are both serving on the Transplant Infectious Diseases Special Interest Group of the American Society of Bone Marrow Transplant.